Neurology News

The FDA has accepted a new drug application for aripiprazole, a 2-month, ready-to-use, long-acting injectable for the treatment of schizophrenia in adults and maintenance monotherapy treatment of bipolar I disorder in adults.

The daily use of multivitamin-mineral supplements improved global cognition, episodic memory and executive function in older adults, researchers reported in Alzheimer’s & Dementia: The Journal of The Alzheimer’s Association.

Amylyx Pharmaceuticals announced that the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted to support approval of the company’s oral, fixed-dose therapeutic AMX0035 for the treatment of ALS.

Edgewise Therapeutics Inc. announced positive 4-month interim results from the ongoing ARCH study of investigational, orally administered EDG-5506 for the treatment of Becker muscular dystrophy in adults.

Low-dose ketamine was generally safe, well-tolerated and effective in treating clinical symptoms in a small group of children with activity-dependent neuroprotective protein syndrome, researchers reported.

Researchers at the University of Kentucky’s Sanders-Brown Center on Aging have received a $20.5 million grant from the National Institute on Aging to study astrocytes and their role in Alzheimer’s disease and other forms of dementia.

An Alzheimer's disease-centered storyline in the primetime television drama series “This Is Us” reduced stigma around dementia and prompted family discussions, researchers reported in the Journal of Health Communications.

Older adults with dementia are at greater risk for SARS-CoV-2 infection and death, highlighting the need for close monitoring of these patients, researchers reported in the Journal for Alzheimer’s Disease.

The FDA has granted breakthrough device designation to Magnus Medical for its neuromodulation treatment of major depressive disorder in adults who failed to achieve improvement from previously prescribed antidepressants.

LAS VEGAS — Results from a nationally representative survey of U.S. adults indicated strong use of various self-care options, with over-the-counter pain relievers the most common, according to a poster presented at PAINWeek 2022.